Login to Your Account



Savient Files Chapter 11; Krystexxa to Remain Available

By Catherine Shaffer
Staff Writer

Wednesday, October 16, 2013
Savient Pharmaceuticals Inc. said that it is committed to keeping Krystexxa on the market throughout and after its bankruptcy process. The struggling biotech filed Chapter 11 voluntarily in the Bankruptcy Court for the District of Delaware, along with a motion seeking authorization to pursue a sale process.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription